Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States (Guardant Health)

Guardant Health and Quest Diagnostics have struck a multi-year deal to make Shield™, the first FDA-approved blood test for colorectal cancer screening, widely available across Quest’s massive network. Starting in early 2026, physicians will be able to order Shield directly through Quest’s EHR system, with patients accessing it at 2,000 service centers and 6,000 in-office phlebotomy sites. By replacing invasive prep with a simple blood draw, the partnership could unlock screening for the 50+ million U.S. adults who currently skip recommended testing — a potential game-changer for early CRC detection and outcomes.